The Marked Chart Wire · Series of events
Series of events · Novo Nordisk
Novo Nordisk raises outlook, then faces eye safety reports
Novo Nordisk lifted its financial forecast after strong sales, followed by Danish reports of eye issues in patients.
Updated
The flow in 3 points
- Wegovy pill sales surpassed estimates in the latest quarter
- Full-year financial outlook was raised on strong demand
- 31 Danish patients reported suspected ocular injuries
What happened, in order
Times are Eastern-
Where it began
Earnings beat
Novo Nordisk reported quarterly earnings that exceeded expectations, driven by Wegovy pill sales that surpassed estimates.
Read the story -
Outlook raised
Novo Nordisk improved its financial outlook, citing sustained demand for its obesity treatments Wegovy and Ozempic.
Read the story -
Latest
Eye issues reported
Regulators in Denmark are treating 31 individuals who reported suspected ocular injuries associated with a Novo Nordisk medication.
Read the story
How they connect
The company first reported strong earnings and then raised its full-year outlook based on demand for its weight loss drugs. This was followed by reports from Denmark regarding suspected eye injuries in patients using the company's medication.
The stocks in this series
Prices from Before the open · based on Thu close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.